Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440617 | 0.85 | NPFFR2 (0.58) | KIF11KDRNOTUMNPFFR2PDK1 | |
| SCHEMBL76697 | 0.85 | NPFFR2 (0.58) | KIF11KDRNOTUMNPFFR2PDK1 | |
| SCHEMBL6139390 | 0.83 | ESRRA (0.55) | KIF11AKR1C3AKR1C2ESRRAMRGPRX4 | |
| SCHEMBL29624981 | 0.83 | TSHR (0.59) | KDRNOTUMKMOMRGPRX4PDK1 | |
| SCHEMBL10532934 | 0.83 | KMO (0.43) | KIF11KDRNOTUMGPBAR1KMO | |
| SCHEMBL24400223 | 0.83 | KMO (0.43) | KIF11KDRNOTUMGPBAR1KMO | |
| SCHEMBL30255650 | 0.83 | NOTUM (0.46) | KIF11KDRNOTUMNPFFR2GPBAR1 | |
| SCHEMBL9526608 | 0.83 | NOTUM (0.46) | KIF11KDRNOTUMNPFFR2GPBAR1 | |
| SCHEMBL1920001 | 0.83 | TSHR (0.59) | KDRNOTUMKMOMRGPRX4PDK1 | |
| SCHEMBL1925084 | 0.82 | KIF11 (0.59) | KIF11NOTUMAKR1C3AKR1C2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4305681-A1 | NEW CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | CREDOXYS GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-116964026-A | Novel cerium (IV) complexes and their use in electronics | 克雷多西斯有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| WO-2022189431-A1 | NEW CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS | Credoxys GmbH (DE) | 2022-09-15 | — | — | WO | disclosed |
| EP-3793559-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| CN-112469412-A | Substituted dihydropyrazolopyrazine carboxamide derivatives | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| EP-1463735-A1 | IMIDAZO[2,1-B]-1,3,4-THIADIAZOLE SULFONAMIDES | Aegera Therapeutics Inc. (CA) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003101970-A1 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
| EP-0365913-B1 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| US-5142092-A | Chemical intermediate for making fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-25 | — | — | US | disclosed |
| EP-0365914-B1 | FLUORINE-CONTAINING ACETOPHENONES OPTIONALLY HALOGENATED IN THE CH3-GROUP, AND THEIR PREPARATION FROM FLUORINATED BENZONITRILES | BAYER AG (DE) | 1992-07-22 | — | — | EP | disclosed |
| US-5104879-A | ANTIMYCOTICALLY ACTIVE SUBSTITUTED 2-AMINOTHIAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| EP-0365914-A2 | Fluorine-containing acetophenones optionally halogenated in the CH3-group, and their preparation from fluorinated benzonitriles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0365913-A2 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324865-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | QDPR, SIRT5, PDXK | KIF11 4211/4885KDR 226/4885NOTUM 2577/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | KIF11 1243/4885KDR 1775/4885NOTUM 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.